MAP Kinase Interacting Serine/Threonine Protein Kinase 2 (MAP Kinase Signal Integrating Kinase 2 or MKNK2 or EC 2.7.11.1) - Pipeline Review, H2 2018

Publisher Name :
Date: 17-Jul-2018
No. of pages: 41

MAP Kinase Interacting Serine/Threonine Protein Kinase 2 (MAP Kinase Signal Integrating Kinase 2 or MKNK2 or EC 2.7.11.1) - Pipeline Review, H2 2018

Summary

MAP Kinase Interacting Serine/Threonine Protein Kinase 2 (MAP Kinase Signal Integrating Kinase 2 or MKNK2 or EC 2.7.11.1) - MAP kinase-interacting serine/threonine-protein kinase 2 is an enzyme encoded by the MKNK2 gene. It phosphorylates SFPQ/PSF, HNRNPA1 and EIF4E. It plays a role in the response to environmental stress and cytokines. It appears to regulate translation by phosphorylating EIF4E thus increasing the affinity of this protein for the 7-methylguanosine-containing mRNA cap. It triggers EIF4E shuttling from cytoplasm to nucleus. It acts as a mediator of the suppressive effects of IFNgamma on hematopoiesis.

MAP Kinase Interacting Serine/Threonine Protein Kinase 2 (MAP Kinase Signal Integrating Kinase 2 or MKNK2 or EC 2.7.11.1) pipeline Target constitutes close to 7 molecules. Out of which approximately 4 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase II, Preclinical and Discovery stages are 1, 1 and 2 respectively.

Similarly, the universities portfolio in Preclinical and Discovery stages comprises 1 and 2 molecules, respectively. Report covers products from therapy areas Oncology, Genetic Disorders and Immunology which include indications Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Diffuse Large B-Cell Lymphoma, Fragile X Syndrome, Inflammation, Metastatic Colorectal Cancer and Non-Small Cell Lung Cancer.

The latest report MAP Kinase Interacting SerineThreonine Protein Kinase 2 - Pipeline Review, H2 2018, outlays comprehensive information on the MAP Kinase Interacting Serine/Threonine Protein Kinase 2 (MAP Kinase Signal Integrating Kinase 2 or MKNK2 or EC 2.7.11.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in MAP Kinase Interacting Serine/Threonine Protein Kinase 2 (MAP Kinase Signal Integrating Kinase 2 or MKNK2 or EC 2.7.11.1) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for MAP Kinase Interacting Serine/Threonine Protein Kinase 2 (MAP Kinase Signal Integrating Kinase 2 or MKNK2 or EC 2.7.11.1)

- The report reviews MAP Kinase Interacting Serine/Threonine Protein Kinase 2 (MAP Kinase Signal Integrating Kinase 2 or MKNK2 or EC 2.7.11.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved in MAP Kinase Interacting Serine/Threonine Protein Kinase 2 (MAP Kinase Signal Integrating Kinase 2 or MKNK2 or EC 2.7.11.1) targeted therapeutics and enlists all their major and minor projects

- The report assesses MAP Kinase Interacting Serine/Threonine Protein Kinase 2 (MAP Kinase Signal Integrating Kinase 2 or MKNK2 or EC 2.7.11.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news and deals related to MAP Kinase Interacting Serine/Threonine Protein Kinase 2 (MAP Kinase Signal Integrating Kinase 2 or MKNK2 or EC 2.7.11.1) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for MAP Kinase Interacting Serine/Threonine Protein Kinase 2 (MAP Kinase Signal Integrating Kinase 2 or MKNK2 or EC 2.7.11.1)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding MAP Kinase Interacting Serine/Threonine Protein Kinase 2 (MAP Kinase Signal Integrating Kinase 2 or MKNK2 or EC 2.7.11.1) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

MAP Kinase Interacting Serine/Threonine Protein Kinase 2 (MAP Kinase Signal Integrating Kinase 2 or MKNK2 or EC 2.7.11.1) - Pipeline Review, H2 2018

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
MAP Kinase Interacting Serine/Threonine Protein Kinase 2 (MAP Kinase Signal Integrating Kinase 2 or MKNK2 or EC 2.7.11.1) - Overview
MAP Kinase Interacting Serine/Threonine Protein Kinase 2 (MAP Kinase Signal Integrating Kinase 2 or MKNK2 or EC 2.7.11.1) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
MAP Kinase Interacting Serine/Threonine Protein Kinase 2 (MAP Kinase Signal Integrating Kinase 2 or MKNK2 or EC 2.7.11.1) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
MAP Kinase Interacting Serine/Threonine Protein Kinase 2 (MAP Kinase Signal Integrating Kinase 2 or MKNK2 or EC 2.7.11.1) - Companies Involved in Therapeutics Development
eFFECTOR Therapeutics Inc
Eli Lilly and Co
Merck & Co Inc
Oncodesign SA
MAP Kinase Interacting Serine/Threonine Protein Kinase 2 (MAP Kinase Signal Integrating Kinase 2 or MKNK2 or EC 2.7.11.1) - Drug Profiles
cercosporamide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
eFT-508 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ETC-17804452 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit MAPKAP Kinase 2 for Inflammation - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit MKNK1 and MKNK2 for Oncology and Unspecified Indication - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit MNK1 and MNK2 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Mnk2 for Acute Myeloid Leukemia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MAP Kinase Interacting Serine/Threonine Protein Kinase 2 (MAP Kinase Signal Integrating Kinase 2 or MKNK2 or EC 2.7.11.1) - Dormant Products
MAP Kinase Interacting Serine/Threonine Protein Kinase 2 (MAP Kinase Signal Integrating Kinase 2 or MKNK2 or EC 2.7.11.1) - Product Development Milestones
Featured News & Press Releases
Jun 06, 2018: eFFECTOR Initiates Dosing of eFT508 in Phase 2 Expansion of Clinical Trial in Aggressive Form of Non-Hodgkin's Lymphoma
May 11, 2018: eFFECTOR Initiates Randomized Dosing in Phase 2 Checkpoint Combination Trial of eFT508 and Avelumab in Colorectal Cancer
Apr 26, 2018: eFFECTOR Publishes the Design and Profile of eFT508 in Peer Reviewed Journal of Medicinal Chemistry
Apr 16, 2018: eFFECTOR to Present Data on eFT508 at the AACR 2018 Annual Meeting
Dec 11, 2017: Clinical Data for eFFECTOR Therapeutics' Lead Candidate eFT508 Demonstrates Clinical Activity, Well-Tolerated Safety Profile
Dec 05, 2017: Oncodesign Reports Positive Results for Its MNK1/2 Program
Nov 10, 2017: eFFECTOR Therapeutics Presents Preclinical Data for eFT508 that Demonstrates Beneficial Immunological Effects
Oct 04, 2017: eFFECTOR Therapeutics Initiates Dosing in Phase 2 Combination Trial of eFT508 and Avelumab in Microsatellite Stable Colorectal Cancer
Jun 05, 2017: eFFECTOR Therapeutics Presents Phase 1 Data On eFT508, Its Lead Product Candidate, At ASCO 2017
Apr 10, 2017: Cancer Genetics is Selected by eFFECTOR Therapeutics to Provide Biomarker Discovery and Development Services for Novel Oncology Drugs
Apr 03, 2017: eFFECTOR Therapeutics Presents Positive Preclinical Data on Lead Product Candidate at AACR 2017
Mar 09, 2017: Effector Therapeutics Lead Product Candidate, EFT508, Receives Orphan Designation From FDA for Treatment of Diffuse Large B-cell Lymphoma
Mar 18, 2016: eFFECTOR Therapeutics to Present at the American Association for Cancer Research 2016 Annual Meeting
Jun 19, 2015: Peer-Reviewed Study in Cell Validates eFFECTOR Therapeutics' Novel Small-Molecule Approach to Cancer Treatment
Jan 06, 2015: eFFECTOR Therapeutics Initiates Dosing in Phase 1/2 Clinical Trial of eFT508 in Solid Tumors
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Indication, H2 2018
Number of Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018
Number of Products under Investigation by Universities/Institutes, H2 2018
Products under Investigation by Universities/Institutes, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Pipeline by eFFECTOR Therapeutics Inc, H2 2018
Pipeline by Eli Lilly and Co, H2 2018
Pipeline by Merck & Co Inc, H2 2018
Pipeline by Oncodesign SA, H2 2018
Dormant Projects, H2 2018

List of Figures
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Top 10 Indications, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
  • Global Endocrinology Drugs Market Insights, Forecast to 2025
    Published: 14-Dec-2018        Price: US 3900 Onwards        Pages: 119
    In 2017, the global Endocrinology Drugs market size was million US$ and is forecast to million US in 2025, growing at a CAGR of from 2018. The objectives of this study are to define, segment, and project the size of the Endocrinology Drugs market based on company, product type, application and key regions. This report studies the global market size of Endocrinology Drugs in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focu......
  • Global Liver Cirrhosis Therapeutics Market Insights, Forecast to 2025
    Published: 14-Dec-2018        Price: US 3900 Onwards        Pages: 114
    In 2017, the global Liver Cirrhosis Therapeutics market size was million US$ and is forecast to million US in 2025, growing at a CAGR of from 2018. The objectives of this study are to define, segment, and project the size of the Liver Cirrhosis Therapeutics market based on company, product type, application and key regions. This report studies the global market size of Liver Cirrhosis Therapeutics in key regions like North America, Europe, Asia Pacific, Central & South America and......
  • Global B4GN4 Antibody Market Insights, Forecast to 2025
    Published: 14-Dec-2018        Price: US 3900 Onwards        Pages: 115
    In 2017, the global B4GN4 Antibody market size was million US$ and is forecast to million US in 2025, growing at a CAGR of from 2018. The objectives of this study are to define, segment, and project the size of the B4GN4 Antibody market based on company, product type, application and key regions. This report studies the global market size of B4GN4 Antibody in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the cons......
  • Global B3GL2 Antibody Market Insights, Forecast to 2025
    Published: 14-Dec-2018        Price: US 3900 Onwards        Pages: 118
    In 2017, the global B3GL2 Antibody market size was million US$ and is forecast to million US in 2025, growing at a CAGR of from 2018. The objectives of this study are to define, segment, and project the size of the B3GL2 Antibody market based on company, product type, application and key regions. This report studies the global market size of B3GL2 Antibody in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the cons......
  • Global C1GLT Antibody Market Insights, Forecast to 2025
    Published: 14-Dec-2018        Price: US 3900 Onwards        Pages: 110
    In 2017, the global C1GLT Antibody market size was million US$ and is forecast to million US in 2025, growing at a CAGR of from 2018. The objectives of this study are to define, segment, and project the size of the C1GLT Antibody market based on company, product type, application and key regions. This report studies the global market size of C1GLT Antibody in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the cons......
  • Global CGAT2 Antibody Market Insights, Forecast to 2025
    Published: 14-Dec-2018        Price: US 3900 Onwards        Pages: 113
    In 2017, the global CGAT2 Antibody market size was million US$ and is forecast to million US in 2025, growing at a CAGR of from 2018. The objectives of this study are to define, segment, and project the size of the CGAT2 Antibody market based on company, product type, application and key regions. This report studies the global market size of CGAT2 Antibody in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the cons......
  • Global GALNT1 Antibody Market Insights, Forecast to 2025
    Published: 14-Dec-2018        Price: US 3900 Onwards        Pages: 127
    In 2017, the global GALNT1 Antibody market size was million US$ and is forecast to million US in 2025, growing at a CAGR of from 2018. The objectives of this study are to define, segment, and project the size of the GALNT1 Antibody market based on company, product type, application and key regions. This report studies the global market size of GALNT1 Antibody in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the c......
  • Global Fucosyltransferase 3 (enzyme) FUT3 Protein Market Insights, Forecast to 2025
    Published: 14-Dec-2018        Price: US 3900 Onwards        Pages: 112
    In 2017, the global Fucosyltransferase 3 (enzyme) FUT3 Protein market size was million US$ and is forecast to million US in 2025, growing at a CAGR of from 2018. The objectives of this study are to define, segment, and project the size of the Fucosyltransferase 3 (enzyme) FUT3 Protein market based on company, product type, application and key regions. This report studies the global market size of Fucosyltransferase 3 (enzyme) FUT3 Protein in key regions like North America, Europe,......
  • Global cDNA Clone Vector Market Insights, Forecast to 2025
    Published: 14-Dec-2018        Price: US 3900 Onwards        Pages: 116
    In 2017, the global cDNA Clone Vector market size was million US$ and is forecast to million US in 2025, growing at a CAGR of from 2018. The objectives of this study are to define, segment, and project the size of the cDNA Clone Vector market based on company, product type, application and key regions. This report studies the global market size of cDNA Clone Vector in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs